Interview: Judith Greciet – CEO, Onxeo, France
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Resulting from the merger of BioAlliance Pharma (France) and Topotarget (Denmark) in July 2014, Onxeo is a new leader in European biotechnology. Thanks to a unique portfolio of advanced stage products and dedicated teams of experts, Onxeo aims to take a leading position in the field of orphan oncology drugs. Through bringing pioneering drugs to market, the company wants to improve patients’ lives, fund continuous investment in R&D of orphan diseases, and create value for all company’s stakeholders and shareholders. It has three strategic programs in advanced development and two products already registered in the European and US markets, demonstrating its teams’ expertise and know-how.
49 boulevard du Général Martial Valin
75015 PARIS, France
Tel: +33 (0)1 45 58 76 00
Fax: +33 (0)1 45 58 08 81
Investors: investors@onxeo.com
Email: contact@onxeo.com
Website: www.onxeo.com
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study…
The latest news from French pharma, including fears of medicine shortages and suspension of online sales of paracetamol, CARMAT’s artificial heart product entering a study in France, Sanofi’s expanded deal…
An early bronchiolitis outbreak has put French paediatric hospital services under pressure and forced the government to react with the provision of EUR 150 million in emergency funds, but this…
French mid-cap Servier has launched a new visual identity and logo and announced an ambitious 2030 growth plan with an increased focus on hard-to-treat cancers. Servier, which is governed…
Exor, led by Fiat brand heirs the Agnelli family, has signed a partnership agreement for an investment of EUR 833 million in the also family-owned French holding, Institut Mérieux, known…
The head of the French Chamber of Commerce in Egypt, Karim Wissa, dives into the current state of the Egyptian economy, the reasons behind its healthcare boom, explains why companies…
France is Europe’s 4th largest pharmaceutical manufacturer, having produced pharmaceuticals valued at €21.9 billion in 2019. In recent years, the French contract development and manufacturing organisation (CDMO) market has seen…
When British executive Paul Hudson joined French pharma Sanofi back in 2019, he was quick to launch a “play to win” strategy, shedding underperforming areas and doubling down on its…
French mid-cap pharma Ipsen achieved total sales of EUR 2.869 billion in 2021, a 12.3 percent increase on results from the pandemic-affected 2020 total. The company also announced plans to…
The latest news from French pharma, including AI-based biotech Owkin’s new status as a USD one billion-valued unicorn following fresh investment from Sanofi. Also included is another deal for Sanofi,…
The Top Five countries in Europe for pharma production. All located in Western Europe, Switzerland punches well above its weight to take top spot. This data is taken from the 2021…
See our Cookie Privacy Policy Here
